本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开的日期、时间： 证券代码：000881 证券简称：中广核技 公告编号：2025-008 中广核核技术发展股份有限公司 2025 年第一次临时股东会决议公告 （1）现场会议召开日期、时间：2025年2月14日（星期五）下午3:30； （2）网络投票日期、时间：通过深圳证券交易所交易系统进行网络投票的具 体时间为：2025年2月14日上午9:15至9:25、9:30至11:30、下午1:00至3:00；通过深 圳证券交易所互联网投票系统投票的具体时间为2025年2月14日上午9:15至下午 3:00期间的任意时间。 2.会议召开方式：本次股东会采取现场投票与网络投票相结合的方式。 3.现场会议召开地点：深圳市福田区深南大道 2002 号中广核大厦北楼 19 层 881 会议室。 4.召集人：公司董事会。 5.主持人：公司半数以上董事推举董事、总经理盛国福先生主持本 ...

为出具本法律意见书之目的，本所委派律师（以下简称"本所律师"）列席了贵 公司本次股东会，并根据有关中国法律、法规的规定及要求，按照律师行业公认的 深圳市福田区中心四路 1-1 号 嘉里建设广场第三座第 2803-04 室 邮编：518048 电话：(86-755) 2939-5288 传真：(86-755) 2939-5289 junhesz@junhe.com 北京市君合（深圳）律师事务所 关于中广核核技术发展股份有限公司 2025 年第一次临时股东会的法律意见书 致：中广核核技术发展股份有限公司 北京市君合（深圳）律师事务所（以下简称"本所"）受中广核核技术发展股份 有限公司（以下简称"贵公司"或"公司"）的委托，就贵公司 2025 年第一次临时股东 会（以下简称"本次股东会"）召开的有关事宜，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》、《上市公司股东大会规则》（以下 简称"《股东大会规则》"）等中国现行法律、法规和规范性文件（以下简称"中国法 律、法规"，为本法律意见书之目的，中华人民共和国（以下简称"中国"，包括香 港特别行政区、澳门特别行政区和台湾省，为出具本 ...

Investment Rating - The report initiates coverage with a "Buy" rating for CGN Technology (000881.SZ) [12] Core Views - CGN Technology is recognized as the leading enterprise in non-power nuclear technology applications in China, part of the China General Nuclear Power Group's "6+1" industrial system [3][19] - The company is currently facing short-term pressure on its performance due to underwhelming new materials business and losses in its cultivation period businesses [22] - The nuclear technology application industry in China has significant growth potential, with the market expected to expand substantially in the coming years [27][28] Summary by Sections Company Overview - CGN Technology is the first stock in non-power nuclear technology and serves as a development platform for non-power nuclear technology applications in China [3][19] - The company focuses on high-performance modified engineering plastics and is a major supplier in various sectors including industrial electrical, automotive, and electronic industries [20] Financial Performance - In 2021, the company achieved a revenue of 79.99 billion yuan, with a year-on-year growth of 20.25%. However, revenues declined by 13.18% and 8.53% in 2022 and 2023 respectively, with a slight recovery in 2024 [22] - The company's net profit for 2023 and the first three quarters of 2024 is projected to be negative due to high costs and competitive pressures [22] New Materials Transition - CGN Technology is optimizing its new materials structure and transitioning towards high-end materials, with traditional product sales expected to grow by approximately 5.5% in the first half of 2024 [4] - The company has seen a significant increase in sales in the "three new" markets, with a year-on-year growth of about 51.8% [4] Accelerator Technology - CGN Technology is a leader in the electronic accelerator market, with a focus on high-energy applications. The company has introduced advanced proton therapy technology and is establishing a production base for proton therapy equipment [5][53] - The market for proton therapy systems in China is projected to be substantial, with a total market size estimated at around 30.7 billion yuan during the 14th Five-Year Plan period [5] Profitability Forecast - The company forecasts a net profit of -3.13 billion yuan in 2024, with a gradual recovery to 1.20 billion yuan in 2025 and 1.90 billion yuan in 2026 [12] - The expected earnings per share (EPS) for 2024, 2025, and 2026 are projected to be -0.33, 0.13, and 0.20 yuan respectively [12]

Financial Performance - The company expects a net loss of between 29 million yuan and 42 million yuan for the year 2024, compared to a net loss of 73.72 million yuan in the same period last year[2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss between 45 million yuan and 64 million yuan, down from a loss of 96.06 million yuan in the previous year[2]. - The basic earnings per share are expected to be a loss between 0.3067 yuan and 0.4442 yuan, compared to a loss of 0.7797 yuan per share last year[2]. Strategic Focus - The company is focusing on its "A+" strategy, with steady progress in operational management, innovation, and reform efforts, particularly in the accelerator and healthcare sectors[4]. - Significant investments are being made in the development and promotion of healthcare, nuclear environmental protection, and silicon photonics businesses, which are currently incurring losses[4]. Market Conditions - The company is experiencing pressure on product prices and gross margins due to industry cycle adjustments and intensified market competition in the new materials business[4]. Asset Management - The company plans to conduct comprehensive asset inspections and impairment tests, with provisions for potential asset impairments[5]. - The preliminary financial data is subject to change, and the final figures will be disclosed in the 2024 annual report[6].

Group 1 - The company 中广核俊尔 (Zhongguang Nuclear Juner) has recently been established with a registered capital of 41.5 million yuan [2] - The legal representative of 中广核俊尔 is 相军 (Xiang Jun) [2] - The business scope of 中广核俊尔 includes manufacturing leather products, plastic products, machinery equipment leasing, import and export of goods, and technology import and export [2] Group 2 - 中广核技 (China General Nuclear Power Corporation) holds 100% ownership of 中广核俊尔 [1]

何祖元先生在任职期间恪尽职守、勤勉尽责，公司及董事会对其在任董事期 间为公司发展做出的贡献表示衷心地感谢。 中广核核技术发展股份有限公司（以下简称"公司"）董事会于 2024 年 12 月 26 日收到非独立董事何祖元先生提交的书面辞职报告，何祖元先生因到龄退 休，申请辞去公司董事及董事会战略委员会委员、董事会薪酬委员会委员职务， 辞职后不再担任公司任何职务。 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》和《公司章程》的有关规定，何祖元先生的辞职 不会导致公司董事会成员低于法定最低人数，不影响董事会的正常运作。何祖元 先生的辞职报告自送达公司董事会之日起生效。公司董事会将按法定程序尽快完 成董事的补选工作。截至本公告披露日，其未持有本公司股份。 证券代码：000881 证券简称：中广核技 公告编号：2024-074 特此公告。 中广核核技术发展股份有限公司 关于董事辞职的公告 中广核核技术发展股份有限公司 董事会 2024年12月28日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 ...

Summary of Conference Call on Nuclear Technology Application Industry and Company Insights Company Overview - The company discussed is 中广核技 (CGN Technology), which focuses on the application of nuclear technology, particularly in non-power sectors. It has been tracked for a significant period and is seen as a leader in the nuclear technology application industry [1][19]. Industry Insights - The nuclear technology application industry encompasses various fields, including industrial, agricultural, food, medical health, and public safety. The International Atomic Energy Agency has noted that the breadth of its applications is comparable only to electronics and new technologies [2]. - A significant policy was introduced by the China Atomic Energy Authority in October, outlining a three-year action plan for the high-quality development of the nuclear technology application industry, aiming for a direct economic output of 400 billion yuan by 2026 [3]. Core Business Segments - The company operates in three main business areas: 1. **Electronic Accelerators and Auxiliary Processing**: This is the core business, with a focus on industrial applications and a market share of approximately 70% in China [23]. 2. **New Materials**: The company is transitioning towards high-value-added products, including materials for renewable energy sectors [11]. 3. **Medical Applications**: Significant investments have been made in proton therapy equipment for cancer treatment, with plans for domestic production of advanced medical devices [8][10]. Financial Performance and Projections - The company reported a loss of 700 million yuan last year, with expectations of a smaller loss this year. However, there are projections for a turnaround, with potential profits of around 200 million yuan in the coming years [5][14]. - The company is expected to benefit from the ongoing reforms in state-owned enterprises and the strategic support from its parent company, 中广核集团 (CGN Group) [4][15]. Strategic Initiatives - The company is actively divesting non-core assets, particularly in real estate and unrelated businesses, to streamline operations and focus on its main areas of expertise [5][13]. - There is an emphasis on enhancing production capacity and integrating external acquisitions to bolster growth in the nuclear technology application sector [6][12]. Market Opportunities - The market for proton therapy equipment is projected to be substantial, with estimates suggesting a potential market size of 100 billion yuan if the rollout of necessary facilities accelerates [10][28]. - The company is also exploring opportunities in the isotope supply chain and aims to enhance its role in the nuclear technology application industry through strategic partnerships and investments [25][24]. Conclusion - The company is positioned to leverage its strengths in nuclear technology applications, supported by favorable government policies and a strategic focus on high-value sectors. The anticipated recovery in financial performance and the potential for significant market growth in medical and new materials sectors present promising investment opportunities [16][30].